Detailed Narrative
Q1 FY27 Performance Overview
Sai Life Sciences reported a robust Q1 FY27, with total revenue reaching INR 553 crores, marking a 12% year-over-year increase from INR 496 crores in the same quarter last year. The CRO business was a significant growth driver, expanding by 26% year-over-year and contributing 40% of the total revenue. The CDMO segment also grew by 6% year-over-year, accounting for 60% of the company's revenues. Management expressed confidence in achieving its mid-term revenue growth guidance of 15-20% and an EBITDA range of 28-30%, anticipating a stronger second half for FY27.
Strategic Evolution to Multi-Modality CRDMO
The company is strategically evolving from a small molecule CRDMO to a technology-led, multi-modality integrated CRDMO, aiming to provide end-to-end services from discovery to commercial manufacturing. This involves building strong R&D capabilities across diverse modalities, including peptides, XDC (Antibody-Drug Conjugates), and formulation. This shift is driven by increasing customer demand for integrated offerings and geopolitical uncertainties, making India a more important part of diversification strategies for pharma companies.
Peptides and XDC Expansion
Sai Life Sciences is making significant investments in new modalities, particularly peptides and XDC. A dedicated peptide development lab is coming online shortly, and plans are underway to break ground for a commercial peptide manufacturing facility near Hyderabad, expected to be operational in 2028 with an estimated capex of less than INR 300 crores. The company is also close to opening its XDC Center of Excellence, which will support discovery and development in payloads, linkers, and conjugation across various modalities.
Capacity Expansion and Operational Readiness
The company's capacity expansion plans are largely on schedule, with a new discovery capacity facility becoming operational in Q1 FY27 and already being fully utilized. The first production block (225 KL) at Bidar, part of a total 450 KL expansion, is expected to come online in H2 or Q3 FY27. Formulation capabilities, focusing on oral solids for clinical phase 1 and 2 supplies, are anticipated to be operationally ready within the current fiscal year, approximately six months away. The FY27 capex guidance remains at INR 1,100-1,300 crores.
Deepening Client Relationships and Pipeline
Sai Life Sciences is focused on building sustained, long-term relationships with large pharmaceutical companies through dedicated FTE (Full-Time Equivalent) models. Over the last 15 months, six late-phase molecules have been added to the pipeline, with five originating from large pharma clients with ongoing FTE engagements. One such collaboration has expanded into a sizable dedicated FTE contract, demonstrating the company's ability to transition clients from early discovery to late-stage manufacturing. Returning customers accounted for over 90% of revenue in FY25 and FY26, highlighting strong client satisfaction.
Scientific and Talent Development Initiatives
The company continues to invest in strengthening its scientific capabilities, infrastructure, and talent. Recent achievements include independent development of ADC bio-conjugation characterization and analysis, and a joint paper with AstraZeneca on reaction kinetics. Talent development is a key focus, with a new campus strategy program, structured management development programs, and increased intensity of the Sai Academy, all aimed at attracting, developing, and retaining scientific and technical talent to support increasingly complex programs and new modalities.